MOTS-c

What is MOTS-c?

The mitochondrion has its own small genome, separate from the DNA in the cell nucleus. In 2015, Lee and colleagues found a short open reading frame within the 12S rRNA gene in this genome and named the 16-amino-acid peptide produced from it MOTS-c (mitochondrial open reading frame of the 12S rRNA-c). According to the study, the main target organ of MOTS-c appears to be skeletal muscle; inside the cell it activates the energy sensor AMPK by suppressing the folate cycle and the purine synthesis tied to it. ^[1]

MOTS-c is a member of a group called “mitochondria-derived peptides”; humanin and SHLPs from the same group are also examined in aging research. ^[2] That it is a peptide the body makes itself does not mean that synthetic MOTS-c given from outside is safe or effective. For the concept of a “research peptide”: What does research peptide mean?

What did animal studies show?

• Metabolism (Lee et al., 2015): In mice, MOTS-c treatment prevented age-related and high-fat-diet-induced insulin resistance and diet-induced obesity. ^[1]
• Exercise capacity: MOTS-c was first described as an “exercise mimetic” because it prevented weight gain in mice made obese with a high-fat diet, increased insulin sensitivity, and increased exercise capacity in obese and aged mice. Muscle loss developing with aging was also reduced in mice fed a high-fat diet. ^[2]

These findings belong to mice. The method of administration and duration used in mice cannot be transferred to humans; whether the effect is in the same direction and of the same size in humans must be tested separately. The same general limit is discussed on the BPC-157 and TB-500 pages.

Has MOTS-c been studied in humans?

Observational associations

According to the review by Miller and colleagues, circulating MOTS-c level in humans declines with age; it has been found low in patients with type 2 diabetes, and the level is inversely associated with body mass index, fasting insulin and the insulin resistance indicator (HOMA-IR). In Japanese men, type 2 diabetes risk has also been associated with a natural gene variant (K14Q) that changes the 14th amino acid of MOTS-c. ^[2]

The same review reports that MOTS-c and humanin are being examined as possible biomarkers for cardiovascular disease: levels were found low in people with dysfunction of the inner lining of blood vessels (endothelium), and in one follow-up study the risk of cardiac events was reported as more than 3 times higher in people with type 2 diabetes whose circulating MOTS-c level was below 167 ng/mL. ^[2] MOTS-c measurement is not a routine laboratory test; this threshold belongs to a single research group.

All of these results show association: they do not prove that low MOTS-c causes diabetes or heart disease, or that giving MOTS-c from outside would prevent them. Disease and weight can themselves change the level of the peptide in the blood.

Clinical trials

Miller and colleagues describe CB4211 as a MOTS-c analog and mention this trial as a clinical trial aimed at fatty liver disease and obesity. The review’s last author, P. Cohen, reports being a consultant to and shareholder of the company to which MOTS-c intellectual property is licensed; Cohen is also among the authors of the 2015 study that described MOTS-c. ^{[2] [1]}

Both trials are industry-sponsored. ^{[3] [4]} As of October 2026, no treatment effect of MOTS-c on weight, blood sugar, muscle or aging in humans has been shown in a published controlled trial. The FDA’s page dated April 22, 2026 also writes that no human exposure data were found for MOTS-c. ^[5] The phase 2a trial seeks to answer this question with a placebo-controlled design.

What are the risks?

The safety profile in humans is unknown. The FDA writes that products containing MOTS-c may carry a significant risk of immune response (immunogenicity) with some routes of administration, and may be complex with respect to peptide-related impurities and identification of the active substance. The FDA states that it found no human exposure data for products containing MOTS-c by any route of administration and that they lack safety information, including whether they could cause harm in humans. ^[5]

Because MOTS-c affected insulin sensitivity and blood sugar regulation in mice, what would happen in humans when it is used together with blood sugar-lowering drugs is unknown. ^[1] That the safety results of the phase 1 trial are not in the registry does not close this gap. ^[3]

Legal status: FDA, WADA and Türkiye

USA (FDA)

The FDA places in “category 2” substances nominated as bulk ingredients for compounded (pharmacy-prepared) drugs that may present significant safety risks. In the September 27, 2024 archived copy of the page, MOTS-c appears in the 503A category 2 table with an addition date of 29 September 2023. ^[10] In the FDA’s page dated April 22, 2026, it is in the table of “substances nominated and withdrawn” because the nominators withdrew the nomination, and the FDA’s assessment above remains on the same page. ^[5] This list is not a drug approval.

For the 23–24 July 2026 advisory committee (PCAC) meeting, the FDA evaluated MOTS-c for obesity and osteoporosis uses; it concluded that the evaluation criteria weigh against adding MOTS-c to the list of substances that may be used in pharmacy compounding, and reiterated that it found no human exposure data. ^[9] On 23 July 2026 the committee, contrary to the FDA experts’ recommendation, advised in favor of inclusion; according to a law firm summarizing the meeting, the vote ended 7 yes, 5 no, 2 abstentions, and adding to the list requires the FDA to conduct a rulemaking process with public comment. ^[11] The recommendation is not binding and does not mean drug approval.

Sport (WADA)

In WADA’s list valid from 1 January 2026, MOTS-c is named in section S4.4.1 among examples of AMP-activated protein kinase (AMPK) activators. Section S4, “hormone and metabolic modulators,” is prohibited at all times, in and out of competition. ^[6]

Türkiye

The Licensed Human Medicinal Products List of TİTCK (Turkish Medicines and Medical Devices Agency) dated October 16, 2026 contains no product with MOTS-c as the active substance. ^[7] Article 19 of Law No. 1262 on Pharmaceutical and Medicinal Preparations (İspençiyari ve Tıbbi Müstahzarlar Kanunu) punishes with imprisonment of one to five years those who manufacture unlicensed preparations and those who knowingly sell, offer for sale or have sold preparations manufactured in this way. The same article provides the same penalty for those who sell, market or advertise a product that is not a preparation with the claim that it diagnoses or treats diseases; importing preparations made abroad without a license for commercial purposes is considered smuggling. ^[8]

For the general framework: Are peptides legal? For another research peptide mentioned with an aging claim: Epitalon.

Limits of this guide

This page summarizes published animal data on MOTS-c, observational findings in humans, registered clinical trials and decisions of official bodies. It gives no dose, course, preparation, administration technique or product sourcing information. Treatments with evidence for prediabetes, diabetes or obesity are determined by physician evaluation.